Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Entrektynib jako pojedynczy środek w początkowej terapii dla dzieci

2 listopada 2026 zaktualizowane przez: St. Jude Children's Research Hospital

Badanie FAZY 2 dotyczące entrektynibu jako pojedynczego leku w początkowej terapii u dzieci

This clinical trial tests how well entrectinib works to treat patients less than 3 years of age with NTRK 1/2/3 or ROS1 fused, high grade glioma or other central nervous system (CNS) tumors.

Przegląd badań

Szczegółowy opis

PRIMARY OBJECTIVE

  • To determine the overall response rate of entrectinib when used as first line therapy in patients who are younger than 3 years of age with NTRK1/2/3- or ROS1-fused high-grade glioma (HGG) (Cohort 1).

SECONDARY OBJECTIVES

  • To estimate the 2-year and 5-year progression free survival (PFS) and overall survival (OS) in patients who are younger than 3 years of age with NTRK1/2/3- or ROS1-fused HGG treated with entrectinib as first line therapy (Cohort 1).
  • To estimate the duration of response (DOR) in patients who are younger than 3 years of age with NTRK1/2/3- or ROS1-fused HGG treated with entrectinib as first line therapy (Cohort 1).
  • To evaluate the fraction of patients with NTRK1/2/3- or ROS1-fused HGG treated who have second surgeries and a gross-total resection after treatment with entrectinib is achieved, overall and by country and hospital (Cohort 1).
  • To describe the overall response rate of entrectinib when used as first line therapy in patients who are younger than 3 years of age with NTRK1/2/3- or ROS1-fused CNS tumors other than HGG (Cohort 2).
  • To estimate the 2-year and 5-year PFS and OS in patients who are younger than 3 years of age with NTRK1/2/3- or ROS1-fused CNS tumors other than HGG treated with entrectinib as first line therapy (Cohort 2).
  • To estimate the duration of response (DOR) in patients who are younger than 3 years of age with NTRK1/2/3- or ROS1-fused CNS tumors other than HGG treated with entrectinib as first line therapy (Cohort 2).
  • To evaluate the fraction of patients with NTRK1/2/3- or ROS1-fused CNS tumors other than HGG who have second surgeries and a gross-total resection after treatment with entrectinib is achieved, overall and by country and hospital (Cohort 2).
  • To describe toxicities experienced by patients younger than 3 years of age treated with entrectinib (Cohort 1 and 2).
  • To evaluate number of patients that are screened for the study and eligible versus enrolled and treated with entrectinib (Cohort 1 and 2).
  • To measure the time intervals (days) from time of initial diagnostic surgery to screening and enrollment in this study (Cohort 1 and 2).

The trial will have 2 cohorts: Cohort 1: patients diagnosed with NTRK1/2/3- or ROS1-fused high-grade glioma (HGG) and Cohort 2: patients diagnosed with NTRK1/2/3- or ROS1-fused CNS tumors other than HGG.

Patients receive entrectinib enterally once daily (QD) on days 1-28 of each cycle. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients requiring bridging therapy prior to starting entrectinib may receive cyclophosphamide intravenously (IV) over 1 hour on day 1, etoposide IV over 1 hour on day 1 and 2, carboplatin IV over 1 hour on day 2, filgrastim subcutaneously (SC) or IV or pegfilgrastim SC on day 3.

A gross total resection or significant debulking may become possible if a response to entrectinib is seen. If surgical resection is performed and a gross total resection is achieved, 24 cycles of entrectinib will be completed, including those before and after surgery.

After treatment, patients will be followed for 5 years.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

52

Faza

  • Faza 2

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Kopia zapasowa kontaktu do badania

Lokalizacje studiów

      • São Paulo, Brazylia, 08270-070
        • Rekrutacyjny
        • Hospital Santa Marcelina
        • Główny śledczy:
          • Sidnei Epelman, MD
        • Kontakt:
      • São Paulo, Brazylia, 04039-001
        • Rekrutacyjny
        • GRAACC Hospital (Grupo de Apoio ao Adolescente e à Criança com Câncer)
        • Kontakt:
        • Główny śledczy:
          • Andrea M. Cappellano, MD
    • São Paulo
      • Barretos, São Paulo, Brazylia, 14784400
        • Rekrutacyjny
        • Hospital de Câncer de Barretos
        • Kontakt:
        • Główny śledczy:
          • Thais J. Vampre, MD
      • Amman, Jordania, 11941
        • Rekrutacyjny
        • King Hussein Cancer Center
        • Kontakt:
          • Nisreen Amayiri, MD
          • Numer telefonu: 6376 (962 6) 5300460
          • E-mail: namayiri@khcc.jo
        • Główny śledczy:
          • Nisreen Amayiri, MD
      • Lima, Peru
        • Rekrutacyjny
        • Instituto Nacional de Enfermedades Neoplásicas
        • Kontakt:
        • Główny śledczy:
          • Rosdali Coronado, MD
    • Tennessee
      • Memphis, Tennessee, Stany Zjednoczone, 38105
        • Rekrutacyjny
        • St. Jude Children's Research Hospital
        • Kontakt:
        • Główny śledczy:
          • Daniel Moreira, MD, MEd
        • Kontakt:

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

Nie starszy niż 3 lata (Dziecko)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria: Screening Phase

  • Age from birth to age <3 years at the time of diagnosis (date of surgical resection/biopsy)
  • Participant with presumed newly diagnosed tumor in the supratentorial compartment
  • Patient must have measurable disease based on RAPNO criteria
  • ≤84 days since surgery (resection or biopsy)
  • Available tumor tissue for central review
  • Parent/guardian has the ability to understand and the willingness to sign a written informed consent document according to institutional guidelines

Exclusion Criteria: Screening Phase

  • Previous exposure to cytotoxic chemotherapy or radiotherapy

Inclusion Criteria: COHORT 1

  • Patients must be <3 years of age at the time of diagnosis (date of surgical resection/biopsy)

  • High-grade glioma (World Health Organization [WHO] grade III or IV) harboring NTRK1/2/3 or ROS1 gene fusions as determined by central pathology review

  • Patients must have measurable disease as defined by RAPNO criteria

  • Patients are eligible at the time of diagnosis, prior to any exposure to chemotherapy, targeted therapy, immunotherapy, cellular therapy or radiation

  • ≤28 days since study screening

  • Lansky score ≥50% and a minimum life expectancy of ≥ 12 weeks

  • Neurologic deficits must have been stable for at least 7 days prior to study enrollment

  • Hemoglobin ≥ 8 g/dL (without transfusion or erythropoietin use within 7 days prior to enrollment)

  • Platelet count ≥ 75,000/µL (without transfusion within 7-day period prior to enrollment)

  • Absolute neutrophil count >1,000/µL

  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5x the upper limit of normal (ULN)

  • Bilirubin ≤ 1.5 x ULN

  • Adequate renal function as defined by the following age-based serum creatinine concentrations:

    • 0 to <1 year: 0.5 mg/dL
    • 1 to <2 years: 0.6 mg/dL
    • 2 to 3 years: 0.8 mg/dL
  • Adequate cardiac function as defined by electrocardiogram (ECG) with Fridericia's corrected QT interval (QTc) ≤ 450 msec and echocardiogram left ventricular ejection fraction (LVEF) >50%

  • Screening and enrollment consents signed

  • Willingness and ability to comply with treatment plan, scheduled visits, laboratory tests and other study procedures

Inclusion Criteria: COHORT 2

  • Patients must be <3 years of age at the time of diagnosis (date of surgical resection/biopsy)

  • CNS tumor other than HGG harboring NTRK1/2/3 or ROS1 gene fusions as determined by central pathology review

  • Patients must have measurable disease as defined by RAPNO criteria

  • Patients are eligible at the time of diagnosis, prior to any exposure to chemotherapy, targeted therapy, immunotherapy, cellular therapy or radiation

  • ≤28 days since study screening

  • Lansky score ≥50% and a minimum life expectancy of ≥ 12 weeks

  • Neurologic deficits must have been stable for at least 7 days prior to study enrollment.

  • Hemoglobin ≥ 8 g/dL (without transfusion or erythropoietin use within 7 days prior to enrollment)

  • Platelet count ≥ 75,000/µL (without transfusion within 7-day period prior to enrollment);

  • Absolute neutrophil count >1,000/µL.

  • ALT and ALT ≤2.5x the upper limit of normal (ULN)

  • Bilirubin ≤ 1.5 x ULN

  • Adequate renal function as defined by the following age-based serum creatinine concentrations:

    • 0 to <1 year: 0.5 mg/dL
    • 1 to <2 years: 0.6 mg/dL
    • 2 to 3 years: 0.8 mg/dL
  • Adequate cardiac function as defined by ECG with QTc ≤ 450 msec and echocardiogram LVEF >50%

  • Screening and enrollment consents signed

  • Willingness and ability to comply with treatment plan, scheduled visits, laboratory tests and other study procedures

Exclusion Criteria: COHORT 1 AND 2

  • Clinically significant medical disorder that could compromise the ability to tolerate study therapy or would interfere with the study procedures or results history
  • History of recent (3 months) symptomatic congestive heart failure
  • Known active, uncontrolled infection (bacterial, fungal, or viral)
  • Receiving enzyme inducing antiepileptic drugs (EIAEDs)
  • Any prior cancer therapy including chemotherapy (excluding Bridging Chemotherapy Cycle), targeted therapy, immunotherapy, cellular therapy, or radiation
  • Receiving another investigational agent concurrently
  • Surgery within 2 weeks prior to treatment enrollment
  • Patients with known hypersensitivity to excipients of the investigational medicinal product
  • Active gastrointestinal disease or malabsorption disorder (e.g. Crohn's disease, ulcerative colitis, short-gut syndrome) that would impair drug absorption
  • Inability to take medication enterally

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Nie dotyczy
  • Model interwencyjny: Zadanie dla jednej grupy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Entrectinib therapy, Cohort 1 and Cohort 2

Cohort 1: Patients who are younger than 3 years of age diagnosed with NTRK1/2/3- or ROS1-fused high-grade glioma (HGG) will receive therapy as outline in Detailed Description.

Cohort 2: Patients who are younger than 3 years of age diagnosed with NTRK1/2/3- or ROS1-fused CNS tumors other than HGG will receive therapy as outline in Detailed Description.

Given IV

Inne nazwy:
  • Paraplatyna®

Given IV

Inne nazwy:
  • VP-16

Given orally (PO) or enterally

Inne nazwy:
  • Rozłytrek

Given intravenous (IV)

Inne nazwy:
  • Cytoxan®

Given subcutaneous (SQ) or IV

Inne nazwy:
  • Filgrastym

Given SQ as part of recommended Bridging Therapy instead of G-CSF.

Inne nazwy:
  • Neulasta

A gross total resection or significant debulking may become possible if a response to entrectinib is seen.

Inne nazwy:
  • Resekcja chirurgiczna

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Overall response rate (ORR) (Cohort 1)
Ramy czasowe: After cycle 4 (each cycle is 28 days).

ORR is defined as the percentage of patients with either partial or complete response assessed at the protocol-defined evaluation timepoint. Overall response will be determined by the central imaging review based on the scheduled evaluations.

After cycle 4 (each cycle is 28 days).

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Progression free survival (PFS) (Cohort 1)
Ramy czasowe: At 2 and 5 years

PFS is defined as the time from initiation of protocol treatment to first event (progressive disease, death due to any cause), or date last follow-up among those who have not had an event. Described using Kaplan Meier method.

At 2 and 5 years
Overall survival (OS) (Cohort 1)
Ramy czasowe: At 2 and 5 years

OS is defined as the time from date of diagnosis to date of death due to any cause or date last follow-up. Described using Kaplan Meier method.

At 2 and 5 years
Duration of response (DOR) (Cohort 1)
Ramy czasowe: Up to 5 years

DOR is defined as time from date of first response (partial or complete) until the date of progression or last follow-up. Described as median time.

Up to 5 years
Patients who have second surgeries (Cohort 1)
Ramy czasowe: Up to 5 years

Percentage of patients who had second surgeries.

Up to 5 years
Patients who undergo gross-total resection after treatment (Cohort 1)
Ramy czasowe: Up to 5 years

Percentage of patients who underwent a gross-total resection.

Up to 5 years
ORR (Cohort 2)
Ramy czasowe: After cycle 4 (each cycle is 28 days).

ORR is defined as the percentage of patients with either partial or complete response assessed at the protocol-defined evaluation timepoint. Overall response will be determined by the central imaging review based on the scheduled evaluations.

After cycle 4 (each cycle is 28 days).
PFS (Cohort 2)
Ramy czasowe: At 2 and 5 years

PFS is defined as the time from initiation of protocol treatment to first event (progressive disease, death due to any cause), or date last follow-up among those who have not had an event. Described using Kaplan Meier method.

At 2 and 5 years
OS (Cohort 2)
Ramy czasowe: At 2 and 5 years

OS is defined as the time from date of diagnosis to date of death due to any cause or date last follow-up. Described using Kaplan Meier method.

At 2 and 5 years
DOR (Cohort 2)
Ramy czasowe: Up to 5 years

DOR is defined as time from date of first response (partial or complete) until the date of progression or last follow-up. Described as median time.

Up to 5 years
Patients who have second surgeries (Cohort 2)
Ramy czasowe: Up to 5 years

Percentage of patients who had second surgeries. [Time Frame: Up to 5 years]

Up to 5 years
Patients who undergo gross-total resection after treatment (Cohort 2)
Ramy czasowe: Up to 5 years

Percentage of patients who underwent a gross-total resection.

Up to 5 years
Incidence of adverse events (Cohort 1 and 2)
Ramy czasowe: Up to 5 years

Percentage of adverse events on therapy including Entrectinib, captured using National Cancer Institute Common Terminology Criteria for Adverse Events 5.0.

Up to 5 years
Number of patients screened versus enrolled and treated (Cohort 1 and 2)
Ramy czasowe: Up to 5 years

Number of enrolled and treated patients as a percentage of number of patients screened and eligible for study.

Up to 5 years
Time from initial diagnostic surgery to screening and enrollment (Cohort 1 and 2)
Ramy czasowe: Up to 5 years

Median time in days from initial surgery to screening and enrollment on study.

Up to 5 years

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Współpracownicy

Śledczy

  • Główny śledczy: Daniel Moreira, MD, MEd, St. Jude Children's Research Hospital

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

1 maja 2026

Zakończenie podstawowe (Szacowany)

1 listopada 2027

Ukończenie studiów (Szacowany)

1 listopada 2032

Daty rejestracji na studia

Pierwszy przesłany

22 lipca 2024

Pierwszy przesłany, który spełnia kryteria kontroli jakości

25 lipca 2024

Pierwszy wysłany (Rzeczywisty)

30 lipca 2024

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

3 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

2 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

Individual participant de-identified datasets containing the variables analyzed in the published article will be made available (related to the study primary or secondary objectives contained in the publication). Supporting documents such as the protocol, statistical analyses plan, and informed consent are available through the CTG website for the specific study. Data used to generate the published article will be made available at the time of article publication. Investigators who seek access to individual level de-identified data will contact the computing team in the Department of Biostatistics (ClinTrialDataRequest@stjude.org) who will respond to the data request.

Ramy czasowe udostępniania IPD

Data will be made available at the time of article publication.

Kryteria dostępu do udostępniania IPD

Data will be provided to researchers following a formal request with the following information: full name of requestor, affiliation, data set requested, and timing of when data is needed. As an informational point, the lead statistician and study principal investigator will be informed that primary results datasets have been requested.

Typ informacji pomocniczych dotyczących udostępniania IPD

  • PROTOKÓŁ BADANIA
  • SOK ROŚLINNY
  • ICF

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj